Vinge has advised Vicore Pharma in connection with a directed share issue of approximately SEK 125 million

Vinge has advised Vicore Pharma, a Swedish rare disease company focused on interstitial lung diseases and related indications, in connection with a directed share issue whereby Vicore Pharma will receive approximately SEK 125 million in issue proceeds.

Vinge advises Safeture in connection with the offer from Adma

Adma Förvaltnings AB has announced a public cash offer to the shareholders of Safeture AB (publ) to acquire all shares in Safeture.

Vinge has advised Pandox in connection with a directed share issue of approximately SEK 3 billion

Vinge has advised the hotel property owner Pandox in connection with a directed share issue of 16,350,000 class B shares, whereby Pandox will receive approximately SEK 3 billion in issue proceeds.

Vinge has advised Aprea Therapeutics in connection with its listing on Nasdaq, New York

Vinge has advised Aprea Therapeutics, Inc. and its subsidiary Aprea Therapeutics AB in connection with its listing on Nasdaq, New York.

Vinge has assisted in connection with Samhällsbyggnadsbolaget’s listing on Nasdaq Stockholm

Vinge has assisted with counselling on securities law and transaction execution in connection with Samhällsbyggnadsbolaget i Norden AB (publ)’s list change of their B‑ and D‑shares from Nasdaq First North Premier Growth Market to Nasdaq Stockholm’s main market.

Vinge has advised EQT AB (publ) in connection with the listing on Nasdaq Stockholm

Vinge has advised EQT AB (publ) (“EQT”) in connection with the offering and listing on Nasdaq Stockholm with first day of trading on 24 September 2019.

Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm

Vinge advises Vicore Pharma Holding AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market.

Vinge advised ZetaDisplay on bond issue

ZetaDisplay AB (publ) has issued a 3.5 year senior unsecured bond loan of SEK 300 million, within a framework amount of SEK 500 million.

Vinge advised Enea on directed share issue

Vinge advised Enea AB (publ) in connection with a directed share issue of SEK 271 million through an accelerated book building procedure. 

Vinge advised Equinor in connection with divestment of shares in Lundin Petroleum and investment

The Norwegian energy company Equinor ASA announced on 7 July that it had agreed with Lundin Petroleum AB (publ) to divest around 54.5 million shares in Lundin Petroleum for a total consideration of around USD 1.56 billion and to acquire 2.6% of the development project Johan Sverdrup for a cash consideration of USD 910 million.  

Vinge advises Calliditas in connection with a directed share issue

The Board of Directors of Calliditas Therapeutics AB (publ) (“Calliditas”) has resolved on a directed new issue of shares, whereby the company will raise proceeds of approximately SEK 210 million, before issue costs.

Vinge has acted for Bergs Timber in connection with its acquisition of Fågelfors Hyvleri and refinancing

Vinge has acted for Bergs Timber in connection with its acquisition of all shares in AB Fågelfors Hyvleri, a company with wood pellet production located in Fågelfors, Sweden. 

Vinge advises Oncopeptides in connection with a directed share issue

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 727 million, before issue costs.

Vinge has advised Ambea on a rights issue

Vinge has advised Ambea AB (publ) on a fully subscribed rights issue, which will provide Ambea with issue proceeds amounting to approximately SEK 1,215 million before costs.

Vinge advises Veoneer in connection with its USD 600 million capital raise

Veoneer, Inc. (“Veoneer”) has completed a USD 600 million capital raise, consisting of two concurrent offerings of USD 420 million of shares of common stock and USD 180 million aggregate principal amount of convertible senior notes due 2024.